GlassScriptPhysician profile
Cynthia K Baldwin
NPI 1639147911
$3,856.85
in general payments reported to CMS, 2019-2025
38 companies · $996 in 2025
The $996 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $227 · 2021: $230 · 2022: $842 · 2023: $548 · 2024: $323 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000 · Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
| Food and Beverage | $867.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,000.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $385.55 | 2019-2023 | Liletta |
| Hologic Sales and Service, LLC | $307.58 | 2021-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $260.74 | 2019-2025 | Veozah, Myrbetriq |
| Intuitive Surgical, INC. | $218.76 | 2022-2025 | |
| Myriad Women'S Health, INC. | $205.05 | 2023 | Myrisk |
| Pfizer INC. | $164.32 | 2019-2023 | |
| Coopersurgical, INC. | $158.91 | 2019 | |
| Therapeuticsmd, INC. | $134.78 | 2019-2022 | |
| Exeltis, USA INC. | $125.18 | 2022-2024 | Slynd |
| Mayne Pharma Commercial LLC | $107.38 | 2022-2023 | |
| Avion Pharmaceuticals | $85.36 | 2019-2023 | Balcoltra |
| Exact Sciences Corporation | $63.58 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $57.92 | 2021-2024 | |
| Becton, Dickinson and Company | $50.92 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.67 | 2019-2022 | |
| Duchesnay USA Incorporated | $38.22 | 2019 | |
| Asensus Surgical, INC. | $37.33 | 2022 | |
| Lupin INC. | $36.70 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $34.01 | 2019 | |
| Novo Nordisk INC | $31.27 | 2022-2023 | Wegovy |
| Baxter Healthcare | $27.60 | 2019 | |
| Currax Pharmaceuticals LLC | $27.25 | 2019-2020 | |
| Smith+Nephew, INC. | $25.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.04 | 2019-2022 | |
| Millicent US INC | $20.04 | 2020 | |
| Daiichi Sankyo INC. | $19.16 | 2022 | |
| Merck Sharp & Dohme LLC | $18.51 | 2023 | Gardasil 9 |
| Pacira Pharmaceuticals Incorporated | $18.50 | 2020 | |
| Indivior INC. | $17.95 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $17.88 | 2019 | |
| Agile Therapeutics, INC. | $17.44 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.65 | 2022 | |
| Ge Healthcare | $14.55 | 2020 | |
| Sumitomo Pharma America, INC. | $13.03 | 2023 | Myfembree |
| Minerva Surgical, INC | $12.50 | 2019 | |
| Myovant Sciences INC. | $12.41 | 2022 | |
| Meditrina | $9.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.